Trial reportEuropean journal of medical research2025
Clinical analysis of 45 cases of chronic respiratory failure treated by noninvasive ventilator combined with bronchodilator and anti-infective drugs.
Trial report in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study is to investigate the therapeutic effects of a non-invasive ventilator combined with bronchodilator and anti-infective drugs in the treatment of 45 cases of chronic respiratory failure.
methods45 chronic respiratory failure patients who were hospitalized to our hospital between August 2019 and January 2022 were chosen as research subjects. They were randomly allocated into two groups using the random number table approach, the control group (n = 21) and the observation group (n = 24), and they were given numbers according to the sequence of treatment. Treatment as usual was given to the control group. The observation group was further treated with a bronchodilator (tiotropium bromide) and an anti-infective drug (piperacillin). The curative effect of each group after treatment was observed and compared.
resultsAfter running a statistical analysis on demographic information from both groups, including gender, age, BMI, and disease severity, the results showed no significant difference between the groups (P > 0.05). There was a statistically significant (P < 0.05) difference between the observation group and the control group in terms of the time it took for temperatures to recover and pulmonary rales to disappear, as well as the time it took for asthma attacks to occur. Prior to therapy, there were no statistically significant differences between the two groups on blood gas indices or inflammatory indices (P > 0.05). After therapy, patients in the experimental group had lower levels of C-reactive protein (CRP) and tumor necrosis factor-alpha (TNF-α) compared to the controls. The oxygenation index and bacterial partial pressure of oxygen (PaO2) were both considerably higher in the experimental group compared to the control group (P < 0.05). There was no significant difference between the two groups' baseline values for any of the lung function indices (P > 0.05). Following treatment, patients in the treated group had significantly higher forced vital capacity (first second forced vital capacity, first second forced vital capacity, contents of FEV1), forced expiratory volume at first second to forced vital capacity (FEVl/FVC), and forced expiratory volume at first second to predicted value (FEV1% predicted value) compared to those in the control group. This difference was statistically significant (P < 0.05). There was a statistically significant (P < 0.05) improvement in clinical efficacy between the observation group and the control group. In neither group did any patients stop taking the medication due to unwanted side effects.
conclusionA noninvasive ventilator combined with tiotropium bromide and piperacillin has accurate efficacy in the treatment of patients with chronic respiratory failure, which can improve the indexes of arterial blood gas and lung function, reduce inflammatory response, promote disease recovery and have high safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.